4.7 Article

The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)

Journal

CLINICAL CANCER RESEARCH
Volume 27, Issue 1, Pages 28-33

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-20-2536

Keywords

-

Categories

Funding

  1. Melanoma Research Alliance team science award [559058]
  2. Dr. Ralph and Marian Falk Medical Research Trust Bank of America
  3. American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) grant
  4. CURE OM initiative
  5. MRF'sCUREOMinitiative

Ask authors/readers for more resources

Uveal melanoma, a rare cancer in adults, poses a challenging treatment due to lack of effective options. However, ongoing clinical trials and novel targets show promise in improving treatment outcomes, highlighting the high interest and unmet needs in this field.
Uveal melanoma is a rare cancer in adults, but its treatment is one of the clinical unmet needs in the melanoma field. Metastatic disease develops in approximately 50% of patients and is associated with poor survival due to the lack of effective treatment options. It provides a paradigm for cancers that show evidence of aberrant G protein-coupled receptor signaling, tumor dormancy, and liver-selective metastatic tropism and are associated with the loss of the BAP1 tumor suppressor. At the Melanoma Research Foundation CURE OM Science Meeting at the Society for Melanoma Research Meeting held in Utah on November 20, 2019, clinicians and researchers presented findings from their studies according to three themes within uveal melanoma: (i) ongoing dinical trials, (ii) molecular determinants, and (iii) novel targets that could be translated into clinical trials. This meeting underscored the high interest in the uveal melanoma research field and the unmet need for effective treatment strategies for late-stage disease. Findings from ongoing clinical trials are promising, and multiple studies show how novel combinatorial strategies inaease response rates. Novel targets and tumor vulnerabilities identified bioinforniatically or through high-throughput screens also reveal new opportunities to target uveal melanoma. The future directions pursued by the uveal melanoma research field will likely have an impact on other cancer types that harbor similar genetic alterations and/or show similar biological properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available